ASTELLAS PHARMA INC Stock News

Foreign investors and businesspeople with exposure to China are becoming increasingly unnerved. And for good reason.

Naoki Okamura, chief executive officer of Japanese drugmaker Astellas Pharma Inc., discusses his company's decision to acquire Iveric Bio Inc., a developer of drugs to treat age-related blindness, f

Iveric Bio Inc shares climbed 16% to $38.01 on Monday after the US drugmaker agreed to be acquired by Japan's Astellas Pharma for $40 per share in cash or total consideration of about $5.9 billion.

Astellas Pharma snapped up Iveric Bio for $5.9 billion in cash, the companies said Monday in an announcement that sent ISEE stock flying. The post Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion

Japan's Astellas agrees to pay $40 a share for Iveric, citing the potential of the biopharmaceutical company's ophthalmology programs.

Astellas Pharma Inc. said Monday that it agreed to acquire Iveric bio Inc. for about $5.9 billion to strengthen its capabilities in the ophthalmology field.

Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2022 Results Conference Call April 27, 2023 3:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Naoki Okamura - Representativ

Investors interested in Medical - Drugs stocks are likely familiar with Astellas Pharma Inc. (ALPMY) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunit

Astellas Pharma Inc. (OTCPK:ALPMF) Q3 2022 Earnings Conference Call February 6, 2023 1:30 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Kenji Yasukawa - President

Astellas Pharma Inc. (OTCPK:ALPMF) Q3 2022 Earnings Conference Call October 31, 2022 4:00 AM ET Company Representatives Kenji Yasukawa - Chief Executive Officer Yoshitsugu Shitaka - CScO, Chief Scient

Astellas Pharma, Inc. (OTCPK:ALPMF) Q1 2022 Earnings Conference Call August 1, 2022 3:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Minoru Kikuoka - CFO Yukio

ALPMY, AKZOY, and AVVID have been added to the Zacks Rank #5 (Strong Sell) List on June 22, 2022.

Twist Bioscience Corporation (NASDAQ: TWST) has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc (OTC: ALPMF) to conduct research activities t

Astellas Pharma, Inc. (OTCPK:ALPMF) Q4 2022 Results Conference Call April 27, 2022 1:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Kenji Yasukawa - President a

Astellas looks posed to exit a period of prolonged weak revenue growth and see acceleration into the mid-to-high single-digits on multiple product/indication approvals.